HomeDMN • FRA
add
Diamyd Medical AB
Previous close
€0.94
Day range
€0.98 - €0.98
Year range
€0.65 - €1.78
Market cap
1.56B SEK
Avg Volume
1.00
P/E ratio
-
Dividend yield
-
Primary exchange
STO
Market news
Financials
Income Statement
Revenue
Net income
| (SEK) | May 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 47.17M | 17.45% |
Net income | -43.88M | -9.50% |
Net profit margin | — | — |
Earnings per share | — | — |
EBITDA | -46.46M | -17.32% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (SEK) | May 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 319.26M | 96.61% |
Total assets | 400.07M | 61.19% |
Total liabilities | 75.40M | 42.93% |
Total equity | 324.67M | — |
Shares outstanding | 137.50M | — |
Price to book | 0.40 | — |
Return on assets | -41.41% | — |
Return on capital | -55.16% | — |
Cash Flow
Net change in cash
| (SEK) | May 2025info | Y/Y change |
|---|---|---|
Net income | -43.88M | -9.50% |
Cash from operations | -43.50M | -18.29% |
Cash from investing | -4.25M | 89.37% |
Cash from financing | 258.96M | 321.52% |
Net change in cash | 215.51M | 1,626.72% |
Free cash flow | -31.45M | -36.16% |
About
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for diabetes. The company is developing two products.
The company is headquartered in Stockholm, and maintains a manufacturing facility in Umeå. Wikipedia
Founded
1984
Website
Employees
30
